Literature DB >> 25990221

NOS Inhibition Modulates Immune Polarization and Improves Radiation-Induced Tumor Growth Delay.

Lisa A Ridnour1, Robert Y S Cheng2, Jonathan M Weiss3, Sukhbir Kaur4, David R Soto-Pantoja4, Debashree Basudhar2, Julie L Heinecke2, C Andrew Stewart3, William DeGraff2, Anastasia L Sowers2, Angela Thetford2, Aparna H Kesarwala5, David D Roberts4, Howard A Young3, James B Mitchell2, Giorgio Trinchieri3, Robert H Wiltrout3, David A Wink2.   

Abstract

Nitric oxide synthases (NOS) are important mediators of progrowth signaling in tumor cells, as they regulate angiogenesis, immune response, and immune-mediated wound healing. Ionizing radiation (IR) is also an immune modulator and inducer of wound response. We hypothesized that radiation therapeutic efficacy could be improved by targeting NOS following tumor irradiation. Herein, we show enhanced radiation-induced (10 Gy) tumor growth delay in a syngeneic model (C3H) but not immunosuppressed (Nu/Nu) squamous cell carcinoma tumor-bearing mice treated post-IR with the constitutive NOS inhibitor N(G)-nitro-l-arginine methyl ester (L-NAME). These results suggest a requirement of T cells for improved radiation tumor response. In support of this observation, tumor irradiation induced a rapid increase in the immunosuppressive Th2 cytokine IL10, which was abated by post-IR administration of L-NAME. In vivo suppression of IL10 using an antisense IL10 morpholino also extended the tumor growth delay induced by radiation in a manner similar to L-NAME. Further examination of this mechanism in cultured Jurkat T cells revealed L-NAME suppression of IR-induced IL10 expression, which reaccumulated in the presence of exogenous NO donor. In addition to L-NAME, the guanylyl cyclase inhibitors ODQ and thrombospondin-1 also abated IR-induced IL10 expression in Jurkat T cells and ANA-1 macrophages, which further suggests that the immunosuppressive effects involve eNOS. Moreover, cytotoxic Th1 cytokines, including IL2, IL12p40, and IFNγ, as well as activated CD8(+) T cells were elevated in tumors receiving post-IR L-NAME. Together, these results suggest that post-IR NOS inhibition improves radiation tumor response via Th1 immune polarization within the tumor microenvironment. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25990221      PMCID: PMC4506231          DOI: 10.1158/0008-5472.CAN-14-3011

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  60 in total

1.  Effect of oxygen on the frequency of chromosome aberrations produced by alpha-rays.

Authors:  J M THODAY; J READ
Journal:  Nature       Date:  1949-01-22       Impact factor: 49.962

2.  The inhibitory potency and selectivity of arginine substrate site nitric-oxide synthase inhibitors is solely determined by their affinity toward the different isoenzymes.

Authors:  R Boer; W R Ulrich; T Klein; B Mirau; S Haas; I Baur
Journal:  Mol Pharmacol       Date:  2000-11       Impact factor: 4.436

3.  Radiation-induced nitric oxide mitigates tumor hypoxia and radioresistance in a murine SCCVII tumor model.

Authors:  Masaki Nagane; Hironobu Yasui; Tohru Yamamori; Songji Zhao; Yuji Kuge; Nagara Tamaki; Hiromi Kameya; Hideo Nakamura; Hirotada Fujii; Osamu Inanami
Journal:  Biochem Biophys Res Commun       Date:  2013-07-02       Impact factor: 3.575

4.  Cell spreading distinguishes the mechanism of augmentation of T cell activation by integrin-associated protein/CD47 and CD28.

Authors:  M I Reinhold; J M Green; F P Lindberg; M Ticchioni; E J Brown
Journal:  Int Immunol       Date:  1999-05       Impact factor: 4.823

5.  Vivo-Morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues.

Authors:  Paul A Morcos; Yongfu Li; Shan Jiang
Journal:  Biotechniques       Date:  2008-12       Impact factor: 1.993

6.  In vitro and in vivo targeted delivery of IL-10 interfering RNA by JC virus-like particles.

Authors:  Meng-Ing Chou; Yu-Fan Hsieh; Meilin Wang; Jinghua Tsai Chang; Deching Chang; Moncef Zouali; Gregory J Tsay
Journal:  J Biomed Sci       Date:  2010-06-24       Impact factor: 8.410

Review 7.  Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy.

Authors:  Wei Liao; Jian-Xin Lin; Warren J Leonard
Journal:  Immunity       Date:  2013-01-24       Impact factor: 31.745

8.  The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation.

Authors:  J A Coulter; H O McCarthy; J Worthington; T Robson; S Scott; D G Hirst
Journal:  Gene Ther       Date:  2008-02-07       Impact factor: 5.250

Review 9.  Sub-cellular targeting of constitutive NOS in health and disease.

Authors:  Yin Hua Zhang; Barbara Casadei
Journal:  J Mol Cell Cardiol       Date:  2011-09-16       Impact factor: 5.000

10.  Longitudinal imaging studies of tumor microenvironment in mice treated with the mTOR inhibitor rapamycin.

Authors:  Keita Saito; Shingo Matsumoto; Hironobu Yasui; Nallathamby Devasahayam; Sankaran Subramanian; Jeeva P Munasinghe; Vyomesh Patel; J Silvio Gutkind; James B Mitchell; Murali C Krishna
Journal:  PLoS One       Date:  2012-11-20       Impact factor: 3.240

View more
  16 in total

1.  Regulation of Cellular Redox Signaling by Matricellular Proteins in Vascular Biology, Immunology, and Cancer.

Authors:  David D Roberts; Sukhbir Kaur; Jeffrey S Isenberg
Journal:  Antioxid Redox Signal       Date:  2017-09-08       Impact factor: 8.401

2.  Macrophage-derived nitric oxide initiates T-cell diapedesis and tumor rejection.

Authors:  Ibrahim M Sektioglu; Rafael Carretero; Noemi Bender; Christian Bogdan; Natalio Garbi; Viktor Umansky; Ludmila Umansky; Katharina Urban; Magnus von Knebel-Döberitz; Veena Somasundaram; David Wink; Philipp Beckhove; Günter J Hämmerling
Journal:  Oncoimmunology       Date:  2016-08-09       Impact factor: 8.110

3.  miR-429 mediates tumor growth and metastasis in colorectal cancer.

Authors:  Yantao Han; Qian Zhao; Jie Zhou; Rui Shi
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

Review 4.  Understanding the tumour micro-environment communication network from an NOS2/COX2 perspective.

Authors:  Debashree Basudhar; Gaurav Bharadwaj; Veena Somasundaram; Robert Y S Cheng; Lisa A Ridnour; Mayumi Fujita; Stephen J Lockett; Stephen K Anderson; Daniel W McVicar; David A Wink
Journal:  Br J Pharmacol       Date:  2018-11-06       Impact factor: 8.739

5.  miR-542-3p inhibits colorectal cancer cell proliferation, migration and invasion by targeting OTUB1.

Authors:  Long Yuan; Peng Yuan; Huijuan Yuan; Zhenlei Wang; Zengci Run; Guanglong Chen; Peng Zhao; Benling Xu
Journal:  Am J Cancer Res       Date:  2017-01-01       Impact factor: 6.166

Review 6.  Nitric Oxide: The Forgotten Child of Tumor Metabolism.

Authors:  Bahar Salimian Rizi; Abhinav Achreja; Deepak Nagrath
Journal:  Trends Cancer       Date:  2017-08-18

7.  miR-146b-5p regulates cell growth, invasion, and metabolism by targeting PDHB in colorectal cancer.

Authors:  Yuanzeng Zhu; Gang Wu; Wenfeng Yan; Han Zhan; Peichun Sun
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

Review 8.  Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression.

Authors:  Debashree Basudhar; Veena Somasundaram; Graciele Almeida de Oliveira; Aparna Kesarwala; Julie L Heinecke; Robert Y Cheng; Sharon A Glynn; Stefan Ambs; David A Wink; Lisa A Ridnour
Journal:  Antioxid Redox Signal       Date:  2016-09-07       Impact factor: 8.401

Review 9.  Molecular Mechanisms of Nitric Oxide in Cancer Progression, Signal Transduction, and Metabolism.

Authors:  Veena Somasundaram; Debashree Basudhar; Gaurav Bharadwaj; Jae Hong No; Lisa A Ridnour; Robert Y S Cheng; Mayumi Fujita; Douglas D Thomas; Stephen K Anderson; Daniel W McVicar; David A Wink
Journal:  Antioxid Redox Signal       Date:  2018-05-02       Impact factor: 8.401

Review 10.  Original insights on thrombospondin-1-related antireceptor strategies in cancer.

Authors:  Albin Jeanne; Christophe Schneider; Laurent Martiny; Stéphane Dedieu
Journal:  Front Pharmacol       Date:  2015-10-29       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.